Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
47 hedge funds and large institutions have $5.69M invested in Accelerate Diagnostics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 46 → 47 (+1)
32% less capital invested
Capital invested by funds: $8.33M → $5.69M (-$2.64M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$110K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$38K |
| 4 |
Jane Street
New York
|
+$37.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
-$401K |
| 2 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$130K |
| 3 |
AC
Armistice Capital
New York
|
-$38.2K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$34K |
| 5 |
Millennium Management
New York
|
-$3.46K |
AXDX Hedge Fund Activity: Q4 2024 in Review
47 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2024, worth a combined $5.69M — down 32% from $8.33M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AXDX positions and 7 closed out — a net gain of 1 holder — while 7 added to existing stakes and 11 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $110K. The largest seller was Griffin Asset Management, cutting an estimated $401K.
- 47 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2024, up from 46 in Q3 2024.
- Funds reported $5.69M of Accelerate Diagnostics stock for Q4 2024, down 32% quarter-over-quarter.
- 8 funds opened new Accelerate Diagnostics positions in Q4 2024 and 7 closed out, a net change of +1 holder.
- The largest Accelerate Diagnostics buyer in Q4 2024 was Renaissance Technologies, an estimated $110K added.
- The largest Accelerate Diagnostics seller in Q4 2024 was Griffin Asset Management, an estimated $401K sold.
Based on aggregated 13F filings for Q4 2024.